By inhibiting the STAT3/MCL1 signaling axis and predisposing NSCLC cells to ferroptosis, our study provides significant insights for the development of innovative combinations to treat advanced NSCLC patients. The gene discussed is MCL1; the disease is non-small cell lung carcinoma.